US · LEXX · BIOTECHNOLOGY
Lexaria Bioscience Corp. (LEXX) intrinsic value and stock valuation
$4.03as of 2026-11-21 · Mkt cap 8.71M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Lexaria Bioscience Corp. DCF and intrinsic value
InvestorsCraft values LEXX with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from LEXX’s statements →
Lexaria Bioscience Corp. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2010–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $710K | $460K | $230K | $260K | $720K |
| Operating income | -$-11.88M | -$-5.75M | -$-6.53M | -$-6.62M | -$-5.69M |
| Net income | -$-11.9M | -$-5.8M | -$-6.66M | -$-7.27M | -$-4.03M |
| EPSd | -$-9.92M | -$-6.99M | -$-15.14M | -$-18.64M | -$-13.9M |
| Operating cash flow | -$-10.45M | -$-4.96M | -$-5.88M | -$-4.88M | -$-3.99M |
| Capital expenditure | -$-20K | -$-40K | -$-170K | -$-50K | -$-80K |
| Free cash flow | -$-10.48M | -$-5M | -$-6.05M | -$-4.93M | -$-4.07M |
| Total assets | $4.18M | $8.87M | $3.08M | $7.83M | $13.3M |
| Total debt | $110K | $140K | $160K | $50K | $100K |
| Net debt | -$-1.69M | -$-6.36M | -$-1.19M | -$-5.76M | -$-10.82M |
| Total equity | $2.6M | $7.66M | $2.68M | $7.63M | $13.1M |
| Cash and short-term investments | $1.97M | $6.56M | $1.48M | $6.16M | $11.8M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $710K | $460K | $230K | $260K | $720K |
| Cost of revenue | $0.00 | $0.00 | $30K | $70K | $180K |
| Gross profit | $700K | $460K | $190K | $180K | $550K |
| Research and development expenses | $8.24M | $2.36M | $3.67M | $1.84M | $1.26M |
| Selling, general and administrative expenses | $4.35M | $3.85M | $3.06M | $4.96M | $4.97M |
| Other expenses | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating expenses | $12.6M | $6.21M | $6.73M | $6.8M | $6.23M |
| Cost and expenses | $12.6M | $6.22M | $6.76M | $6.87M | $6.41M |
| Interest income | $0.00 | $10K | $40K | $0.00 | $0.00 |
| Interest expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation and amortization | $90K | $80K | $150K | $100K | $150K |
| Ebitda | -$-11.82M | -$-5.73M | -$-6.57M | -$-7.28M | -$-4.02M |
| Operating income | -$-11.88M | -$-5.75M | -$-6.53M | -$-6.62M | -$-5.69M |
| Total other income/expenses, net | -$-30K | -$-60K | -$-180K | -$-760K | $1.52M |
| Income before tax | -$-11.91M | -$-5.81M | -$-6.71M | -$-7.38M | -$-4.16M |
| Income tax expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$-11.9M | -$-5.8M | -$-6.66M | -$-7.27M | -$-4.03M |
| Weighted average shares outstanding | $1.2M | $830K | $440K | $390K | $290K |
| Weighted average diluted shares outstanding | $1.2M | $830K | $440K | $390K | $290K |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $1.97M | $6.56M | $1.48M | $6.16M | $11.8M |
| Net receivables | $170K | $150K | $180K | $200K | $340K |
| Inventory | $0.00 | $0.00 | $0.00 | $40K | $30K |
| Total current assets | $3.47M | $7.9M | $2.2M | $6.98M | $12.4M |
| Property, plant and equipment, net | $330K | $390K | $420K | $370K | $460K |
| Goodwill and intangible assets | $310K | $520K | $460K | $490K | $360K |
| Long-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $710K | $970K | $880K | $860K | $820K |
| Total assets | $4.18M | $8.87M | $3.08M | $7.83M | $13.3M |
| Accounts payable | $1.37M | $1.06M | $230K | $120K | $100K |
| Short-term debt | $30K | $30K | $30K | $40K | $50K |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $1.49M | $1.1M | $270K | $190K | $150K |
| Long-term debt | $80K | $110K | $140K | $10K | $50K |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $80K | $110K | $140K | $10K | $50K |
| Capital lease obligations | $110K | $140K | $160K | $50K | $90K |
| Total liabilities | $1.57M | $1.21M | $400K | $200K | $200K |
| Common stock | $20K | $20K | $10K | $10K | $10K |
| Retained earnings | -$-63.46M | -$-51.56M | -$-45.76M | -$-39.1M | -$-31.83M |
| Accumulated other comprehensive income (loss) | -$-70K | -$-20K | $0.00 | $0.00 | $0.00 |
| Total equity | $2.6M | $7.66M | $2.68M | $7.63M | $13.1M |
| Total investments | $170K | $60K | $130K | $350K | $830K |
| Total debt | $110K | $140K | $160K | $50K | $100K |
| Net debt | -$-1.69M | -$-6.36M | -$-1.19M | -$-5.76M | -$-10.82M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-11.91M | -$-5.81M | -$-6.71M | -$-7.38M | -$-4.19M |
| Depreciation and amortization | $90K | $80K | $150K | $100K | $150K |
| Stock-based compensation | $860K | $490K | $170K | $750K | $410K |
| Change in working capital | $200K | $110K | $140K | -$-350K | $60K |
| Accounts receivable | -$-210K | -$-50K | $30K | -$-140K | $190K |
| Inventory | $0.00 | $0.00 | $40K | -$0.00 | $100K |
| Accounts payable | $0.00 | $830K | $90K | $50K | $10K |
| Net cash provided by operating activities | -$-10.45M | -$-4.96M | -$-5.88M | -$-4.88M | -$-3.99M |
| Investments in property, plant and equipment | -$-20K | -$-40K | -$-30K | -$-50K | -$-80K |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for investing activities | -$-240K | -$-190K | -$-170K | -$-180K | $190K |
| Common stock issued | $6.05M | $4.21M | $1.59M | $0.00 | $9.47M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $6.05M | $10.3M | $1.59M | -$-40K | $13.4M |
| Net change in cash | -$-4.7M | $5.15M | -$-4.46M | -$-5.1M | $9.62M |
| Cash at end of period | $1.8M | $6.5M | $1.35M | $5.81M | $10.9M |
| Operating cash flow | -$-10.45M | -$-4.96M | -$-5.88M | -$-4.88M | -$-3.99M |
| Capital expenditure | -$-20K | -$-40K | -$-170K | -$-50K | -$-80K |
| Free cash flow | -$-10.48M | -$-5M | -$-6.05M | -$-4.93M | -$-4.07M |
Line items
Line items
Line items
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp. is a biotechnology company focused on advanced drug delivery. Its proprietary and patented DehydraTECH technology is designed to significantly improve the oral delivery of active pharmaceutical ingredients, enhancing their absorption into the bloodstream. This innovative platform has shown impressive results, boosting the bioavailability of compounds such as cannabinoids and nicotine by 5 to 10 times, and in some cannabinoid applications, by as much as 27 times, when compared to standard formulations. DehydraTECH also drastically cuts the time of onset from hours to mere minutes and effectively neutralizes unpleasant tastes. Beyond its established uses, the technology is currently under evaluation for its potential application with orally administered antiviral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, and various other compounds. A notable feature of DehydraTECH is its capacity to facilitate the passage of drugs across the blood-brain barrier. The company operates a licensed internal research facility and holds a substantial intellectual property portfolio, comprising 23 granted patents and roughly 50 pending patent applications globally. Founded in 2004, Lexaria Bioscience Corp. is headquartered in Kelowna, Canada.
- CEO
- Richard C. Christopher
- Employees
- 7
- Beta
- 0.34
Explore
Frequently asked questions
What is the intrinsic value of Lexaria Bioscience Corp. (LEXX)?
InvestorsCraft does not currently publish an intrinsic value for LEXX. How the IC value is calculated.
Is LEXX undervalued?
InvestorsCraft does not publish an undervaluation signal for LEXX at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.